AUS
NZ
UK
CA
USA
IND
Highlights
- Orthocell registers first US revenue for Remplir™
- Strategic groundwork supports US market entry
- Strong cash position to support international expansion
Orthocell (ASX:OCC) has marked a pivotal moment in its commercial journey with the recording of its first revenue from the United States for its nerve repair device, Remplir™. This follows the product’s initial surgical use in Ohio on 26 June, with subsequent cases also reported in Florida.
The milestone demonstrates a swift transition from regulatory approval to monetisation. Just three months ago, Orthocell secured 510(k) clearance from the US FDA for Remplir™, and its entry into clinical settings signals a promising start to capturing share within the estimated US$1.6 billion peripheral nerve repair market. This rapid progress also underscores the broader momentum seen among ASX healthcare stocks, with companies like Orthocell positioning themselves to capitalise on innovation-led opportunities in global medical markets.
While Orthocell is not part of the ASX 200 share price index, this early commercialisation step enhances its visibility as an emerging player with global potential. Strategic placements within Ambulatory Surgery Centers are designed to foster familiarity with the product, helping clinicians gain hands-on experience. This model mirrors the company’s successful go-to-market approach in Australia, where early adoption laid the foundation for broader usage.
The company has successfully validated its logistics and order fulfilment capabilities in the US through established partnerships, ensuring timely product delivery and accurate invoicing. Inventory for the US market is now actively managed, enabling continued supply as demand builds.
Financially, Orthocell is well-positioned to support further commercial expansion. With a healthy cash reserve and no debt reported as of 30 June 2025, the company has the flexibility to deepen its reach into the US healthcare landscape while exploring new markets.
The approach undertaken by Orthocell is deliberate and growth-focused. By targeting smaller-scale, early-phase surgical applications, the company can build practitioner trust and clinical validation — a foundational step before wider integration into hospitals and larger medical networks.
Looking forward, Orthocell anticipates continued growth in the adoption of Remplir™ through the second half of 2025. Its market penetration strategy is firmly rooted in execution and repeatability, setting the stage for broader commercial outcomes in the US and beyond. With a solid infrastructure in place, the momentum achieved so far suggests that Orthocell may be on a trajectory to becoming a noteworthy player in the global regenerative medicine space.
